WHO ICTRP trial
A controlled randomised double-blind multicentre study comparing two therapy…
ISRCTN36745608 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN36745608 |
|---|---|
| Public title | A controlled randomised double-blind multicentre study comparing two therapy strategies in disease modifying anti-rheumatic drug-naive early rheumatoid arthritis patients over 48 weeks: induction therapy with adalimumab and methotrexate over 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate monotherapy |
| Primary sponsor | Charité - University Medicine Berlin (Germany) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Germany |
| Conditions | Early rheumatoid arthritis Musculoskeletal Diseases Early rheumatoid arthritis |
| Interventions | Patients will be randomised into one of following groups to receive: 1. Adalimumab (ADA) and MTX over 24 weeks followed by MTX monotherapy up to week 48 2. MTX monotherapy and placebo All subjects will receive MTX subcutaneously (15… |
| Registration date | Nov 8, 2006 |
| Target size | 180 |
| Secondary IDs | 2006-003146-41;50021031-2 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: